U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 2 of 2 results

GALUNISERTIB

MORE DETAILS

  3OKH1W5LZE

Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
TGF-beta receptor type I
6
Conditions:
Myelodysplastic syndromes
58
Rectal adenocarcinoma
2
Hepatocellular carcinoma
83
Prostate cancer
178
Glioblastoma
65
Pancreatic ductal adenocarcinoma
14
Breast cancer
434
Galunisertib is a potent inhibitor of TGF beta type 1 receptor. The drug is under clinical development for the treatment of different cancers: pancreatic, hepatocellular, breast, rectal, prostate etc. and reached phase 2/3 in patients with myelodyspl...

GALUNISERTIB MONOHYDRATE

MORE DETAILS

  338K210Q5W

Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
TGF-beta receptor type I
6
Conditions:
Myelodysplastic syndromes
58
Rectal adenocarcinoma
2
Hepatocellular carcinoma
83
Prostate cancer
178
Glioblastoma
65
Pancreatic ductal adenocarcinoma
14
Breast cancer
434
Galunisertib is a potent inhibitor of TGF beta type 1 receptor. The drug is under clinical development for the treatment of different cancers: pancreatic, hepatocellular, breast, rectal, prostate etc. and reached phase 2/3 in patients with myelodyspl...
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966